Core Insights - The article highlights the emergence of prodrug technology as a pivotal strategy in drug development, showcasing its ability to enhance drug delivery and efficacy through chemical modifications that allow drugs to bypass biological barriers and release at targeted sites [1][19]. Group 1: Prodrug Technology Development - Prodrug technology has evolved from a tool for optimizing pharmacokinetics to a core strategy in drug development, with significant advancements in the last sixty years [19]. - The development of prodrugs has gone through several stages, including simple esterification, guided structural prodrugs, and microenvironment-triggered prodrugs, each enhancing the precision and effectiveness of drug delivery [13][14][15]. Group 2: Dr. He Gongxin's Contributions - Dr. He Gongxin has played a crucial role in the development of prodrug technology, having worked at Gilead for nearly 30 years and contributing to the creation of several internationally recognized prodrugs, including tenofovir alafenamide (TAF) [3][5]. - After establishing a strong foundation in synthetic and medicinal chemistry, Dr. He founded Kejun Pharmaceutical in Shanghai in 2018, focusing on the next generation of prodrug technology using AI and spatial chemistry [6][8]. Group 3: Kejun Pharmaceutical's Innovations - Kejun Pharmaceutical has developed several innovative drugs with global market potential based on its A-ProX AI prodrug technology platform, including CG-0255 and CG-0416, which show promise as Best-in-Class therapies [8][10]. - CG-0255, a novel P2Y12 receptor antagonist, overcomes limitations of traditional antiplatelet drugs by utilizing a hydrolyzed prodrug design, leading to rapid onset of action and improved safety profiles [9][10]. - CG-0416 targets metabolic-associated fatty liver disease (MASH) and demonstrates significant efficacy in reducing liver fat accumulation and inflammation, with promising clinical data supporting its use in combination therapies [10][11]. Group 4: Future Prospects - The integration of AI and spatial chemistry in prodrug design is expected to propel the industry into a new era of intelligent, precise, and personalized medicine, addressing unmet clinical needs and enhancing drug development efficiency [15][19]. - As prodrug technology continues to advance, it is anticipated to provide innovative solutions across various disease areas, completing the value chain from molecular modification to patient benefit [19].

新华财经上海8月1日电（林郑宏） 随着A股7月行情收官，当月A股涨幅榜也正式出炉。 得益于创新药板块的大幅上扬，排除7月上市的新股后，广生堂（300436.SZ）以218.94%的涨幅位居A股月内涨幅榜次席，仅次于"一月十倍"的现象级个股 上纬新材（688585.SH）。 连亏四年，股价飙升？ 广生堂全名为福建广生堂药业股份有限公司，于2015年4月22日在深交所上市。 中经社行业洞察产业服务数据平台（简称"行业洞察系统"）显示，广生堂是专注于肝病及抗病毒、抗感染治疗药物领域的国家重点高新技术企业，也是拥有 五大抗乙肝病毒临床用药的企业。公司坚持从传统仿制药企向创新药企转型的发展战略，持续引进和开发一类创新药和高端仿制药。公司下设多个子业务单 元，畅销品种十几款，涵盖肝病、男科、心血管、中成药等领域。 | 序号 | 发布日期 ◆ | 资质类别 | 资质名称 | 认定年度 ⇒ | | --- | --- | --- | --- | --- | | 1 | 2025-01-07 | 专精特新中小企业 | 省级专精特新中小企业 | 2025 | | 2 | 2024-12-30 | 高新技术企业 | 国家级高新技术 ...